PAGAVO Medicinal Oil and Its Effect on Preventing Acute Radiation Dermatitis in Breast Cancer Patients Undergoing Radiation Therapy

Formulation of PAGAVO Medicinal Oil and Its Effect on Preventing Acute Radiation Dermatitis in Breast Cancer Patients Undergoing Radiation Therapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240915063053N1

Enrollment

Registered

2024-09-23

Start date

2024-09-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Radiation Dermatitis. Acute radiodermatitis

Interventions

Intervention 1: Intervention group: A (drug). This study utilizes PAGAVO Medicinal Oil (PAGAVOs) as the intervention. The ointment is formulated with organic and natural compounds suitable for both or

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Voluntary Participation of Patients Obtaining Written Informed Consent Confirmed Diagnosis of Breast Cancer Administration of a Minimum Dose of 50 Grays During Radiotherapy Treatment

Exclusion criteria

Exclusion criteria: Having conditions such as various tumors, skin lesions, rashes, ulcers, or unhealed scars at the radiotherapy site History of Connective Tissue Disease Concurrent Chemotherapy Previous Radiation Therapy

Design outcomes

Primary

Measure	Time frame
Severity/Grade of Dermatitis. Timepoint: Patients will be visited one week after the start of treatment, followed by weekly visits throughout the treatment period, and a final visit one month after treatment completion. These assessments will evaluate the severity and grade of dermatitis, as well as the presence of symptoms such as burning, itching, and pain in each patient. Method of measurement: The severity of dermatitis will be assessed using the standard RTOG grading system through objective evaluation and by inquiring about the presence of symptoms with the patient.	—

Measure

Time frame

Severity/Grade of Dermatitis. Timepoint: Patients will be visited one week after the start of treatment, followed by weekly visits throughout the treatment period, and a final visit one month after treatment completion. These assessments will evaluate the severity and grade of dermatitis, as well as the presence of symptoms such as burning, itching, and pain in each patient. Method of measurement: The severity of dermatitis will be assessed using the standard RTOG grading system through objective evaluation and by inquiring about the presence of symptoms with the patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sahel Heydarheydari

Ahvaz University of Medical Sciences

sheydari7@gmail.com+98 61 3311 5521

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026